In the design, Otsuka’s orally taken antipsychotic drug ABILIFY” (aripiprazole) incorporates a miniature sensor which records, via a wearable device and a web-based portal for healthcare providers and caregivers, if the drug is ingested and data on activity level of the patient, as well as self-reported rest and mood. In a first step, Otsuka will identify a limited number of appropriate adults with schizophrenia, bipolar I disorder, or major depressive disorder who may benefit from this new digital medicine system.1 This limited rollout is purposeful, as having fewer people using the system initially means their prescribers, health plans, and Otsuka can focus on learning from these patients’ experiences.”

Otsuka Pharmaceutical news release, November 14, 2017